바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.57 No.3
Citation Share

Concurrent Docetaxel/Cisplatin and Thoracic Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2004, v.57 no.3, pp.257-264






& (2004). Concurrent Docetaxel/Cisplatin and Thoracic Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. Tuberculosis & Respiratory Diseases, 57(3), 257-264.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background:There are many combinations of treatment for locally advanced non-small cell lung cancer (NSCLC). Recent studies have showed the efficacy of concurrent chemoradiotherapy (CCRT) in NSCLC. At present, however, there is no consensus about the optimal dosages and timing of radiation and chemotherapeutic agents. The aims of study were to determine the feasibility, toxicity, response rate, and survival rate in locally advanced NSCLC patients treated with doxetaxel and cisplatin based CCRT. Method:Sixteen patients with unresectable stage III NSCLC were evaluated from May 2000 until September 2001. Induction chemoradiotherapy consisted of 3 cycles of docetaxel (75 mg/m2/IV on day 1) and cisplatin (60 mg/m2/IV on day 1) chemotherapy every 3 weeks and concomitant hyperfractionated chest irradiation (1.15 Gy/BID, total dose of 69 Gy) in 6 weeks. Patient who had complete or partial response, and stable disease were applied consolidation chemotherapy of docetaxel and cisplatin. Results:All patients showed response to CCRT. Four patients achieved complete response (25%), partial responses in 12 patients (75%). The major common toxicities were grade III or more of neutropenia (87.3%), grade III esophagitis (68.8%), pneumonia (18.8%) and grade III radiation pneumonitis (12.5%). Thirteen patients were ceased during follow-up period. Median survival time was 19.9 months (95% CI; 4.3-39.7 months). The survival rates in one, two, and three years are 68.7%, 43.7%, and 29.1%, respectively. Local recurrence was found in 11 patients (66.8%), bone metastasis in 2, and brain metastasis in 1 patient. Conclusion:The response rate and survival time of CCRT with docetaxel/cisplatin in locally advanced NSCLC were encouraging, but treatment related toxicities were high. Further modification of therapy seems to be warranted. (Tuberc Respir Dis 2004; 57:257-264)

keywords
Non-small cell lung cancer, Locally advanced, Concurrent chemoradiotherapy.국소 진행성 비소세포 폐암에서 Docetaxel Cisplatin을 사용한 화학방사선 동시치료의 효과고신대학교 복음병원 내과, 방사선 종양학과*장태원, 박정필, 김희규, 옥철호, 정태식*, 정만홍Concurrent Docetaxel/Cisplatin and Thoracic Radiotherapy for Local

Reference

1.

(2002) Annual report of cancer registry program in the Republic of Korea,

2.

(2004) Treatment of Lung Cancer, Koonja

3.

(1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer:First analysis of a randomized trial in 353 patients,

4.

(2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer,

5.

(1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non- small cell lung cancer,

6.

(1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non- small cell lung cancer. A meta-analysis,

7.

(2000) Final Results of phase III trial in regionally advanced unresectable non-small cell lung cancer,

8.

(1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer,

9.

(1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin,vindesin and cisplatin in unresectable stage III non-small cell lung cancer,

10.

(2003) Treatment of stage IIIA non-small cell lung cancer,

11.

(2001) Integration of new chemotherapeutic agents into chemoradio therapy for stage III non-small cell lung cancer,

12.

(1981) reporting the results of cancer treatment,

13.

(1999) The national survey of lung cancer in Korea,

14.

Phase II trial of sequential VP-16 cisplatin combination chemotherapy and radiotherapy for locally advanced,

15.

(1979) Combination chemotherapy and cross- resistance studies with tumors of mice,

16.

(2002) Preliminary results of paclitaxel, cisplatin, and concurrent high-dose radiation therapy for locally advanced non-small-cell lung cancer,

17.

(2003) Guidelines on treatment of stage IIIB non-small cell lung cancer,

18.

(2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIb non-small-cell lung cancer,

19.

(2002) Therapy for stage IIIb and stage IV non-small cell lung cancer,

20.

(2002) Docetaxel/radiation combinations:rationale and preclinical findings,

21.

(2002) Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small cell lung cancer,

22.

(2001) Integration of new chemotherapeutic agents into chemoradio therapy for stage III non-small cell cancer,

23.

(2002) Concurrent docetaxel and thoracic radiation in non-small cell lung cancer,

24.

(2001) Factors affecting the risk of brain metastasis after definitive chemoradiation for locally advanced non-small cell lung cancer,

25.

(2001) Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced non-small cell lung cancer,

26.

(2002) Preliminary report of locally advanced multimodality protocol (LAMP),

27.

Effect of chemotherapy on locally advanced non-small cell lung carcinoma a randomized study of 353 patients,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy